NEW ORLEANS, La., May 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- NutraCea (OTC Bulletin Board: NTRZ) announced today that an open label study at the University of California, Davis, under the auspices of two noted gastroenterologists, Dr. Eliot Drell and Dr. Robert Pecha, has resulted in the launch of the first "SynBiotic (TM) " formulas addressing different health concerns associated with poor intestinal performance at Digestive Disease Week in New Orleans, LA on May 15-20.
Dr. Eliot Drell stated, "Dr. Pecha and I have been conducting an open label trial on our patients using a combination of pre- and probiotics based on NutraCea's proprietary stabilized rice bran derivatives and have seen amazing results in a variety of gastrointestinal problems. We went on to formulate what we believe are three of the most potent, effective nutraceutical treatments available today, and we're introducing them to our peers and to the industry at this medical conference.
"These SynBiotic(TM) formulas are unique in that they combine high-quality probiotics with proprietary prebiotics in capsules that are enteric-coated. Prebiotics feed and encourage the growth of the probiotic bacteria. More clinical trials are underway to demonstrate the power of these natural whole- food products," said Drell.
"For the first time, potent probiotics have been formulated with the most nutrient-dense, hypoallergenic whole-food matrix delivery system we have ever analyzed," stated Dr. Rukmini Cheruvanky, Chief Science Officer for NutraCea and former Deputy Director of the National Institute of Nutrition, Hyderabad, India. "There are many probiotic products on the market today, but none are formulated with prebiotics that encourage the formation of beneficial bacteria so essential to the creation of an environment conducive to human health. We have also developed a way to ensure that the bacteria meet label claims when we sell the probiotics."
Dr. Drell's past medical staff appointments include acting as Director of the Endoscopic unit at Mercy Hospital of Folsom, CA, Director of the Endoscopic Unit at Marshall Hospital, Chief of Medicine at Mercy Hospital of Folsom, Member of the Medical Executive Committee at both Mercy Hospital of Folsom and Marshall Hospital as well as Assistant Professor at the UC Davis Medical Center. He is board-certified in both internal medicine and gastroenterology, which he has practiced for the past 20 years.
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterolgy, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 15-20, 2004 in New Orleans, Louisiana. The meeting displays approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.
NutraCea (OTC Bulletin Board: NTRZ) is emerging as a pioneering, science- based growth company. NutraCea is focused on becoming the world's leading nutraceutical company through the development and distribution of its proprietary stabilized rice bran "super foods," natural arthritic relief products for humans and animals and "all natural" cosmeceuticals and beauty aids. The company is headquartered at 1261 Hawk's Flight Court, El Dorado Hills, California 95762.
This release contains statements that are forward-looking. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.